Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosure (1)
- Disclosure (2)
- The liver
- Liver disease
- Current approaches
- Grand challenges
- Pluripotent stem cells
- Chemically defined differentiation
- Efficient hepatocyte specification
- Drug metabolism and transporter expression
- Pathway analysis
- Benchmarking with industry
- Defining the ECM
- Improved function
- Improved gene expression
- Semi-automated differentiation and screening
- Metabolic dysfunction in hepatic steatosis
- Product development
- Multiple applications and disciplines
- Stemnovate
- Rapid cell dedifferentiation in 2D culture
- Three-dimensional differentiation
- Microwell differentiation
- Scalable liver sphere formation
- Stable liver phenotype in vitro
- Developing an implant – chemistry
- Developing an implant – engineering
- Scaffold loading
- Use of implant to treat metabolic liver disease
- Scaffold implantation
- Rescuing metabolic liver disease in vivo
- Hepatocyte T cell modulation
- Refining tissue engineering
- Liver sphere function
- Disease modelling – fatty liver disease
- Disease modelling – cancer cell metastasis
- Tissue engineering automation
- Stimuliver
- How it works
- Summary
- Acknowledgements
Topics Covered
- Pluripotent stem cells
- Tissue engineering
- Liver
- Hepatocyte
- In vitro modelling
- Implantable liver tissue
Links
Series:
Categories:
External Links
Talk Citation
Hay, D.C. (2023, May 31). Building implantable human liver tissue from pluripotent stem cells [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 4, 2024, from https://doi.org/10.69645/XQST4758.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. David C. Hay has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, my name is David
Hay. I'm Professor of
Tissue Engineering at the
University of Edinburgh's
Centre for
Regenerative Medicine.
Today, I'm gonna
talk about "Building
Implantable Human Liver Tissue
from Pluripotent Stem Cells".
0:16
I have a couple of disclosures
before we go any further.
I'm founder, director
and shareholder of
Stemnovate Limited
based in Cambridge, UK.
0:26
I'm also founder, CEO,
and shareholder in Stimuliver,
a company based in
Copenhagen at the
BioInnovation Institute.
0:36
Our interest is in the liver and
the liver is a highly
organised organ.
It's comprised of
four lobes. Each of
those lobes has an
organised lobule structure.
This organisation of
the lobule structure is
essential for the liver's
multifunctional capacity,
which has been estimated to have
over 500 functions within
the body and also,
this is very important for
liver regeneration when
the liver is damaged.
What we see happening
in the disease process
is the gradual breakdown
of this lobule structure.
This leads to loss
of liver function,
loss of liver regeneration, and
can lead to the onset
of liver disease.
1:19
What does liver disease
look like in the UK?
This is a growing disease and
a growing concern, where we see
some major causes of
death decrease or
stabilise over the
last 50 years,
liver disease has increased
fourfold, and this is
why I'm interested in
studying liver disease to try
and find ways to understand
the disease process
in more detail,
and to try and find ways to
reverse the disease process.
Amid model liver biology
in the dish and
more recently our
generating implantable
tissue for
liver disease patients in
the clinic in the future.